FDA Approves $3.1M Gene Therapy for Rare, Painful Skin DisorderThe FDA has approved Zevaskyn for treating recessive dystrophic epidermolysis bullosa, a rare skin condition, promising improved healing.
New Drug Helps Patients with Myasthenia Gravis Breathe and Speak EasierThe FDA has approved Johnson & Johnson's Imaavy for myasthenia gravis, benefiting over 90% of patients and improving daily tasks.
New FDA-Approved Pill Targets Constant Hunger in Children with PWSFDA approves Soleno's Vykat XR for treating hyperphagia in Prader-Willi Syndrome, aiming to improve patients' quality of life.
Neurocrine's New CAH Drug, Krenicity, Gets FDA Approval—Here’s What You Need to KnowFDA approves Neurocrine Biosciences' Krenicity for congenital adrenal hyperplasia, reducing glucocorticoid dosage in patients.
Must-Reads
1
Will Korea-China summit rekindle hopes of K-culture comeback in China?
LATEST
2
Workers may soon be able to ignore late-night work messages
LATEST
3
International matchmakers under scrutiny over consumer harm
LATEST
4
Nearly 25 Islamic State fighters killed or captured in Syria, US military says
LATEST
5
Hanwha Life wins ISO certification for AI security
FDA Approves $3.1M Gene Therapy for Rare, Painful Skin Disorder The FDA has approved Zevaskyn for treating recessive dystrophic epidermolysis bullosa, a rare skin condition, promising improved healing.
New Drug Helps Patients with Myasthenia Gravis Breathe and Speak Easier The FDA has approved Johnson & Johnson's Imaavy for myasthenia gravis, benefiting over 90% of patients and improving daily tasks.
New FDA-Approved Pill Targets Constant Hunger in Children with PWS FDA approves Soleno's Vykat XR for treating hyperphagia in Prader-Willi Syndrome, aiming to improve patients' quality of life.
Neurocrine's New CAH Drug, Krenicity, Gets FDA Approval—Here’s What You Need to Know FDA approves Neurocrine Biosciences' Krenicity for congenital adrenal hyperplasia, reducing glucocorticoid dosage in patients.
Hot Topics